Open AccessAssociation of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs
Author(s) -
SR Taur,
NB Kulkarni,
PP Gandhe,
B.K. Thelma,
SH Ravat,
NJ Gogtay,
Thatte Um
Publication year - 2014
Publication title -
journal of postgraduate medicine/journal of postgraduate medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 52
eISSN - 0972-2823
pISSN - 0022-3859
DOI - 10.4103/0022-3859.138739
Subject(s) - medicine , cyp2c19 , cyp2c9 , pharmacology , p glycoprotein , pharmacogenetics , epilepsy , glycoprotein , genetics , genotype , gene , cytochrome p450 , psychiatry , metabolism , drug resistance , multiple drug resistance , biology
Epilepsy, the most common neurological disorder, has treatment failure rate of 20 to 25%. Inter-individual variability in drug response can be attributed to genetic polymorphism in genes encoding different drug metabolizing enzymes, drug transporters (P-gp), and enzymes involved in sodium channel biosynthesis. The present study attempted to evaluate association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and P-gp activity with treatment response in patients with epilepsy.